Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)

China flag China · Delayed Price · Currency is CNY
27.30
-0.62 (-2.22%)
Apr 21, 2026, 3:04 PM CST
Market Cap5.51B +167.3%
Revenue (ttm)1.68B +40.1%
Net Income253.16M
EPS1.29
Shares Out201.78M
PE Ratio21.13
Forward PE24.16
Dividend0.20 (0.72%)
Ex-Dividend DateAug 26, 2025
Volume9,859,682
Average Volume11,760,337
Open27.85
Previous Close27.92
Day's Range27.14 - 27.98
52-Week Range19.08 - 32.62
Beta0.81
RSI58.02
Earnings DateApr 17, 2026

About Wuhan Hvsen Biotechnology

Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founde... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,028
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300871
Full Company Profile

Financial Performance

Financial Statements